KS

Kommineni Suryasarmista Chowdry

Active Director Director DIN 10673521
DIN 10673521 First appointment Jun 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Kommineni Suryasarmista Chowdry

Data last updated:

Kommineni Suryasarmista Chowdry is a Director at Sarmista Pharmaceuticals Private Limited (since 2024). The company operates in Pharma.

DIN 10673521
Primary Designation Director
Industry Pharma
First Appointment 19 Jun 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Jun 20242024Active

Board colleagues of Kommineni Suryasarmista Chowdry

NameDINCompanyDesignation
Pargi Anand10673520Sarmista Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Sarmista Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Kommineni Suryasarmista Chowdry

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kommineni Suryasarmista Chowdry

Kommineni Suryasarmista Chowdry currently holds 1 directorship: Sarmista Pharmaceuticals Private Limited (Director, since 19 Jun 2024).

Kommineni Suryasarmista Chowdry was first appointed on 19 Jun 2024 as Director at Sarmista Pharmaceuticals Private Limited.

The current boards of Kommineni Suryasarmista Chowdry's companies include Pargi Anand (Sarmista Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available